EN DE
Watch Tempus AI, Inc. Class A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Tempus AI, Inc. Class A (TEM) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Tempus AI, Inc. Class A stock $52.58, price $64.76, that is 18.8% below the price, quality 37 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US88023B1035

TA Tempus AI, Inc. Class A logo Thin data Nov 10, 2026

Tempus AI, Inc. Class A

TEM · US

Expensive (fair value 19% below the price), weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Recent news mostly positive 
Revenue last quarter +23% vs. a year ago. 
Price moving sideways (no uptrend) 
Expensive Growth (revenue 5y +46.6 %/yr in USD) 
Insiders sold $125.3M (6M) 
Fair value $52.58 · Overvalued 
Quality 37/100 
Loss-making · -12.5% net margin (TTM) 
High debt 
Negative free cash flow 
Trails peers (1/9) 
Narrow moat 12/100
Thin data 
Estimate

Main risks:

🚩Foundation models could reduce data licensing demand🚩Roche could replicate data moat via FMI and Flatiron🚩Privacy lawsuits or reimbursement scrutiny on genetic data
Watch Tempus AI, Inc. Class A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$103.25 $24.96 Fair Value $52.58 Jun 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

29‑month range $24.96 – $103.25 · fair‑value band $39.43 – $65.72 · the $64.76 price screens above the $52.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Tempus AI, Inc. Class A in your weekly email

Every Wednesday you see whether Tempus AI, Inc. Class A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tempus AI, Inc. operates as a healthcare technology company in the United States.

Show moreShow less

It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests.

The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.

In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling.

Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application.

It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia.

The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Stock analysis

Tempus AI, Inc. Class A (TEM) currently trades at $64.76, while our estimate is $52.58, 19% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $39.43 (bear) to $65.72 (bull), the price of $64.76 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Tempus AI, Inc. Class A reported revenue of $1.3B in FY2025 versus $258M in FY2021, a compound +49.0%/yr. Reported net income was −$245M in FY2025.

Key figures

Market cap $10.9B Large · P/S ratio 8.51 · EPS (TTM) $−1.06 · Net margin −12.5% · Return on equity −37.6% · Return on assets (EBIT) −41.6% (5-year average) · Operating margin −13.8% · Revenue (TTM) $1.5B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 24% below its 52-week high and 56% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −35% fair-value upside, at −19%, TEM screens cheaper than that median.

Fair Value

Bear $39.43 Fair Value $52.58 Bull $65.72
Price $64.76 · Downside -18.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 21
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 9
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 72
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 41
Distance to the 52-week high, does not count
New shares 28
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 9 officers or directors sold shares worth $125.3M and none bought.

  • SaleDavid R EpsteinDirector7× since Dec 1, 2025: 2,110 shares, avg. $59.63$125,825Nov 2, 202610b5-1 plan
  • SaleRyan FukushimaCEO, Data14× since Nov 18, 2025: 217,350 shares, avg. $55.97$12.2MNov 2, 2026
  • SaleEric P LefkofskyCEO and Chairman, Director, 10% owner17× since Nov 18, 2025: 2,881,592 shares, avg. $62.05$178.8MOct 27, 2026
  • SaleThomas Edward SchoenherrCEO, Diagnostics3× since May 19, 2026: 29,175 shares, avg. $64.22$1.9MSep 25, 2026
  • SaleRyan M BartolucciChief Accounting Officer5× since Nov 18, 2025: 22,089 shares, avg. $59.26$1.3MSep 17, 2026
  • SaleAndrew PolovinEVP, Chief Legal Officer6× since Nov 18, 2025: 85,287 shares, avg. $58.98$5.0MSep 17, 2026
  • SaleJennifer A DoudnaDirector4× since Dec 1, 2025: 5,275 shares, avg. $60.21$317,611Sep 1, 202610b5-1 plan
  • SaleNadja WestDirector2× since Aug 14, 2026: 6,000 shares, avg. $61.45$368,700Aug 28, 202610b5-1 plan
  • SaleJames William RogersChief Financial Officer7× since Nov 18, 2025: 119,945 shares, avg. $57.69$6.9MAug 19, 2026
  • SaleErik PhelpsEVP, Chief Admin. Officer3× since Nov 18, 2025: 14,299 shares, avg. $61.67$881,800Feb 19, 2026

Plus 1 more entries from the last 12 months.

Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+83.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+65.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−102.9% (2020) → −18.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

TEM screens overvalued: fair value 19% below the price. Compare with Veeva Systems Inc →

Recent news

News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Nov 12, 2026
AI conclusion: Tempus holds a narrow moat through licensing structured diagnostic datasets to pharmaceutical companies, yet sustained net losses, negative free cash flow and high leverage limit durable advantage.
Main risk: Large foundation models trained on public or alternative data could allow pharma companies to advance drug development without licensing Tempus's de-identified multimodal datasets, hitting its high-margin Data and Applications segment.
Tempus turns diagnostic testing volume into structured datasets that it licenses to pharmaceutical companies. The data and applications segment grew faster than core testing last quarter, but a sizable portion still comes from a related party connected to the founder. Our models see it as overvalued. Does the rising number of independent big-pharma data deals reduce reliance on that channel, or does the mix remain a structural feature of the business?
Join the discussion →

Compare Tempus AI, Inc. Class A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 140 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −18.8% · Below median
Profitability
Return on assets −10.8% · Below median
Net margin (12 months) −12.5% · Below median
Operating margin (12 months) −13.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 23.1% · Above median
Balance sheet
Debt / equity 2.70× · Highest 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 22.27× · book value is mostly intangible assets ⓘGoodwill and other intangible assets (such as prices paid for past acquisitions, brands, licences or film and series rights) are larger than the equity. So we do not rank this P/B against the peer group.
P/S (12 months) 7.25× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)8 · sector 15
FUTURE (revenue growth)100 · sector 46
PAST (return on equity)0 · sector 3
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)0 · sector 44

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Doximity, Inc DOCS $32.77 $36.67 +12% vs TEM
Veeva Systems Inc VEEV $299.28 $329.21 +10% vs TEM
HealthEquity, Inc HQY $104.58 $115.04 +10% vs TEM
Waystar Holding WAY $28.11 $29.10 +4% vs TEM
HeartFlow, Inc HTFL $46.86 $30.50 −35% vs TEM
Hinge Health, Inc HNGE $121.29 $51.25 −58% vs TEM
Pro Medicus Limited PME A$201.65 A$82.80 −59% vs TEM
BrightSpring Health Services, Inc BTSG $71.37 $25.72 −64% vs TEM
XtalPi Holdings 2228 HK$5.53 HK$1.53 −72% vs TEM
Privia Health Group PRVA $25.26 $5.52 −78% vs TEM

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tempus AI, Inc. Class A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Tempus AI, Inc. Class A Fair Value". https://www.fairvalue-calculator.com/stock/TEM

Frequently asked questions

Is Tempus AI, Inc. Class A (TEM) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $52.58 versus a price of $64.76, about 19% lower (overvalued).
What is the fair value of TEM?
Our estimate for Tempus AI, Inc. Class A is $52.58 (as of Nov 10, 2026), built from audited fundamentals. The current price: $64.76.
What is the quality score of TEM?
Tempus AI, Inc. Class A has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tempus AI, Inc. Class A (TEM)?
Our calculated price target is the estimate of $52.58 (as of Nov 10, 2026). Cautious scenario $39.43, optimistic scenario $65.72. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Tempus AI, Inc. Class A stock forecast for 2026?
Our estimate puts fair value at $52.58, about 19% lower versus a price of $64.76 (overvalued). Cautious scenario $39.43, optimistic scenario $65.72. The calculation is refreshed regularly with new filings.
What is the revenue of Tempus AI, Inc. Class A (TEM)?
Tempus AI, Inc. Class A reported trailing-twelve-month revenue of about $1.5B (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Tempus AI, Inc. Class A (TEM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tempus AI, Inc. Class A it is $52.58 per share (as of Nov 10, 2026), against a price of $64.76.
Is Tempus AI, Inc. Class A stock overvalued or undervalued in 2026?
As of Nov 10, 2026, TEM trades above its calculated fair value: price $64.76, fair value $52.58, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TEM?
No. The price is what the market pays today ($64.76); the fair value is what the company's own numbers justify ($52.58). For Tempus AI, Inc. Class A the two are $12.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tempus AI, Inc. Class A worth?
The market values Tempus AI, Inc. Class A at about $10.9B (market capitalisation, as of Nov 10, 2026). Per share that is $64.76; our models calculate a fair value of $52.58 per share.
What do the bullish and bearish scenarios say about TEM?
Our models span a range for Tempus AI, Inc. Class A: cautious scenario $39.43, base $52.58, optimistic $65.72 per share (as of Nov 10, 2026, price $64.76). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Tempus AI, Inc. Class A (TEM)?
Balance-sheet figures for Tempus AI, Inc. Class A (as of Nov 10, 2026): return on equity −37.6%, debt of 2.70 per unit of equity (balance sheet 30 Sep 2026). They feed the Quality Score of 37/100, which uses the fiscal-year figures and measures business quality independently of the share price.
How far is TEM from its 52-week high?
Tempus AI, Inc. Class A trades at $64.76, about 24% below its 52-week high of $85.08 and 56% above the low of $41.55 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $52.58 is for.
Which stocks are comparable to Tempus AI, Inc. Class A?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tempus AI, Inc. Class A stock attractive at the current price?
The data as of Nov 10, 2026: price $64.76, calculated fair value $52.58 (−19%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Tempus AI, Inc. Class A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tempus AI, Inc. Class A (TEM)?
The closing price on Nov 16, 2026 was $64.76. Our estimate is $52.58, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tempus AI, Inc. Class A right now?
Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Tempus AI, Inc. Class A

How large is the market capitalisation of Tempus AI, Inc. Class A (TEM)?
The market capitalisation of Tempus AI, Inc. Class A is $10.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tempus AI, Inc. Class A (TEM)?
The price-to-sales ratio of Tempus AI, Inc. Class A is 8.51 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tempus AI, Inc. Class A (TEM)?
Earnings per share at Tempus AI, Inc. Class A are $−1.06. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Tempus AI, Inc. Class A (TEM)?
The net margin of Tempus AI, Inc. Class A is −12.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tempus AI, Inc. Class A (TEM)?
The return on equity (ROE) of Tempus AI, Inc. Class A is −37.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tempus AI, Inc. Class A (TEM)?
On an EBIT basis the return on assets of Tempus AI, Inc. Class A is −41.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tempus AI, Inc. Class A (TEM)?
The operating margin of Tempus AI, Inc. Class A is −13.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tempus AI, Inc. Class A (TEM)?
Revenue at Tempus AI, Inc. Class A is growing 23.1% versus a year earlier (3y avg +58.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Tempus AI, Inc. Class A (TEM) generate?
The free cash flow of Tempus AI, Inc. Class A is −$239M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tempus AI, Inc. Class A (TEM) carry?
The net debt of Tempus AI, Inc. Class A is $841M (balance sheet 30 Sep 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Tempus AI, Inc. Class A in the live analysis

One click puts Tempus AI, Inc. Class A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.